Clinical trials: Stage II Hypertension
- Condition Stage II Hypertension
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Hypertension
Rheos® Pivotal Trial
The purpose of this clinical trial is to demonstrate the efficacy and safety of the Rheos system in subjects with hypertension that are resistant to treatment with at least three anti-hypertension agents, one of which is a…
- Trial name
- NCT00442286
- Testing
- Rheos® Baroreflex Hypertension System
- Where
- 44 sites in United States, Germany and 1 more
- Volunteers
- 591 people
- Sponsor
- CVRx, Inc.
Stage II Hypertension
Candesartan Effect in Second Stage Arterial Hypertension
To compare the changes in mean sitting DBP from baseline after 4 weeks of therapy with either candesartan cilexetil/HCT combination therapy or candesartan cilexetil monotherapy regimen
- Trial name
- CAESAR (NCT00621153)
- Testing
- Candesartan Cilexetil, Hydrochlorothiazide
- Where
- South Korea
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Hypertension
A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients
This study will evaluate the efficacy and safety of nebivolol monotherapy in Hispanic patients with stage 1 or stage 2 hypertension
- Trial name
- NCT00770861
- Testing
- Nebivolol
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 277 people
- Sponsor
- Forest Laboratories
Hypertension
Nebivolol in Patients With Systolic Stage 2 Hypertension
The primary object of this study is to evaluate the efficacy and safety of 6 weeks of nebivolol monotherapy compared with placebo in patients with systolic stage 2 hypertension.
- Trial name
- NEB-MD-20 (NCT01057251)
- Testing
- Nebivolol
- Where
- 36 sites in United States
- Volunteers
- 433 people
- Sponsor
- Forest Laboratories
Hypertension
Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension
The purpose of the study is to evaluate the blood pressure lowering effect and safety of aliskiren in combination with Hydrochlorothiazide (HCTZ) compared to aliskiren monotherapy when given to metabolic syndrome patients with…
- Trial name
- AIMS (NCT00797316)
- Testing
- Aliskiren, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 532 people
- Sponsor
- Novartis
Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
To evaluate the efficacy and safety of 26-weeks of treatment with riociguat vs. placebo in patients with symptomatic PH (pulmonary hypertension) associated with IIP (idiopathic interstitial pneumonias).
- Trial name
- RISE-IIP (NCT02138825)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 93 sites in United States, Argentina and 19 more
- Volunteers
- 147 people
- Sponsor
- Bayer
Hypertension
A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension
This 16 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with moderate to severe high blood pressure in comparison to placebo.
- Trial name
- NCT00430638
- Testing
- olmesartan medoxomil + hydrochlorothiazide, if necessary
- Where
- 29 sites in United States
- Volunteers
- 278 people
- Sponsor
- Daiichi Sankyo
Stage 2 Diastolic Hypertension
Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension
This study will evaluate the safety and efficacy of first-line treatment with a free combination (as two separate pills) of nebivolol and lisinopril in patients with stage 2 diastolic hypertension (DBP>= 100 mmHg).
- Trial name
- NCT01218100
- Testing
- nebivolol and lisinopril (free combination), nebivolol monotherapy, lisinopril monotherapy
- Where
- 90 sites in United States, Puerto Rico
- Volunteers
- 664 people
- Sponsor
- Forest Laboratories
Pulmonary Hypertension
Safety of SonoVue on Pulmonary Hemodynamics
This is an intra-subject crossover comparative safety study to evaluate the effect of intravenous (IV) bolus injection of SonoVue on pulmonary hemodynamics.
- Trial name
- NCT01306292
- Testing
- SonoVue
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Bracco Diagnostics, Inc
Hypertension
Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension
Study to Evaluate the Efficacy and Safety of Aliskiren Hydrochlorothiazide (HCTZ) vs Ramipril in Obese patients (BMI ≥ 30) with Stage 2 Hypertension
- Trial name
- ATTAIN (NCT00772577)
- Testing
- Aliskiren Hydrochlorothiazide, Ramipril
- Where
- 6 sites in United States
- Volunteers
- 386 people
- Sponsor
- Novartis
Hypertension
Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension
The purpose of the study is to compare the combination of aliskiren, amlodipine and Hydrochlorothiazide (HCTZ) versus the combination of aliskiren and amlodipine as therapy in minority Stage 2 hypertensive patients.
- Trial name
- ASCENT (NCT00942994)
- Testing
- Aliskiren/Amlodipine, Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)
- Where
- 5 sites in United States
- Volunteers
- 412 people
- Sponsor
- Novartis
Open Angle Glaucoma, Ocular Hypertension
SYL040012, Treatment for Open Angle Glaucoma
The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28…
- Trial name
- SYLTAG (NCT02250612)
- Testing
- 1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran)
- Where
- 21 sites in United States, Estonia and 2 more
- Volunteers
- 184 people
- Sponsor
- Sylentis, S.A.
Hypertension, Pulmonary
Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension
The primary objective of this study is to evaluate the effect of GSK1325760A on improvement in exercise capacity in subjects with pulmonary arterial hypertension (PAH).
- Trial name
- NCT00540436
- Testing
- GSK1325760A
- Where
- 15 sites in Japan
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Hypertension
A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension
This study assessed the blood pressure effect, safety and tolerability of LCI699 compared to placebo and eplerenone in participants with resistant hypertension.
- Trial name
- NCT00817635
- Testing
- LCI699, Eplerenone
- Where
- 38 sites in United States, Iceland
- Volunteers
- 155 people
- Sponsor
- Novartis
Essential Hypertension
Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
In patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of hydrochlorothiazide (2…
- Trial name
- Benibest (NCT00890591)
- Testing
- olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
- Volunteers
- 144 people
- Sponsor
- Daiichi Sankyo
Hypertension, Coronary Artery Disease
The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease
This study is being done to see if the blood pressure lowering effect of an approved drug nebivolol is comparable to that of another approved drug carvedilol for the treatment of hypertension in patients who have coronary artery…
- Trial name
- NCT00673075
- Testing
- Nebivolol, Carvedilol
- Where
- 34 sites in United States
- Volunteers
- 39 people
- Sponsor
- Forest Laboratories
Hypertension
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension
This 14 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients 65 years of age or older with high blood pressure.
- Trial name
- NCT00412932
- Testing
- Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide
- Where
- 29 sites in United States
- Volunteers
- 178 people
- Sponsor
- Daiichi Sankyo
Hypertension, Renal
Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension
A randomized, double-blind, placebo-controlled, dose-ranging, Phase II study to evaluate the safety, efficacy, and tolerability of MLS-101 in Subjects With Uncontrolled Hypertension
- Trial name
- Target-HTN (NCT05001945)
- Testing
- MLS-101 (Part I), MLS-101 (Part II)
- Where
- 44 sites in United States
- Volunteers
- 200 people
- Sponsor
- Mineralys Therapeutics Inc.
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG
Phase II, randomized, double-masked study to evaluate the efficacy and tolerability of topical ocular delivery of fixed-dosed combinations of trabodenoson and latanoprost in subjects with Ocular Hypertension or Primary Open-Angle…
- Trial name
- NCT02829996
- Testing
- trabodenoson 6.0% / latanoprost 0.005% QD, trabodenoson 3.0% / latanoprost 0.005% QD, trabodenoson 6.0% / latanoprost 0.0025% QD
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Hypertension
Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension
The purpose of the study is to evaluate the BP-lowering efficacy of the combination of aliskiren and amlodipine, as initial therapy, compared to amlodipine monotherapy in African American patients with Stage II hypertension.
- Trial name
- AACESS (NCT00853957)
- Testing
- Aliskiren/Amlodipine, Amlodipine
- Where
- 9 sites in United States
- Volunteers
- 443 people
- Sponsor
- Novartis